A Phase I-II, Blinded, Randomized, Placebo-controlled Study of a T Cell Priming Next-generation Vaccine Against Coronavirus Disease in Healthy Adults
Latest Information Update: 28 Feb 2025
At a glance
- Drugs PepGNP-SARSCoV2 (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease; Severe acute respiratory syndrome
- Focus Adverse reactions
- Acronyms naNO-COVID 2
- Sponsors Gylden Pharma
Most Recent Events
- 24 Feb 2025 Protocol was amended as dose changed from 38.3ug to 47.8ug.
- 24 Feb 2025 Planned End Date changed from 23 Oct 2024 to 1 Dec 2026.
- 24 Feb 2025 Planned primary completion date changed from 23 Mar 2024 to 1 Jun 2026.